Новые возможности в лечении артериальной гипертонии


Цитировать

Полный текст

Аннотация

Несмотря на большие усилия, предпринимаемые для эффективного контроля артериальной гипертонии, достичь целевых значений артериального давления (АД) удается у меньшинства больных. Одним из новых представителей блокаторов рецепторов ангиотензина II 1-го типа (БРА), обладающих стабильным антигипертензивным эффектом, является азилсартана медоксомил. Антигипертензивный эффект азилсартана превосходит действие некоторых других БРА, поэтому расширяются возможности его применения в виде монотерапии. У больных non-dipper с нарушениями циркадного ритма АД азилсартан может быть препаратом выбора.

Об авторах

Ирина Ивановна Чукаева

ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва

д-р мед. наук, проф., зав. каф. поликлинической терапии

Фатима Даутовна Ахматова

ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва

Email: a.fa.da@mail.ru
канд. мед. наук, доц. каф. поликлинической терапии

Список литературы

  1. Wolff-Maier K, Cooper R.S, Banegas J.R et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289 (18): 2363-9.
  2. Whitworth J.A and World Health Organization, International Society of Hypertension Writing Group. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21 (11): 1983-92.
  3. Grassi G, Cifkova R, Laurent S et al. Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. Eur Heart J 2011; 32: 218-25.
  4. Kotsevaa K, Wooda D, De Backerb G et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16 (2): 121-37.
  5. Graettinger W F 2003 Systemic Hypertension. In: Crawford M.H (eds). Current Diagnosis and Treatment in Cardiology 2nd edn. Mac Graw Hill Professional: New York, NY, USA; p. 167-78.
  6. Appel G.B, Appel A.S. Angiotensin II receptor antagonists: role in hypertension, cardiovascular disease, and renoprotection. Prog Cardiovasc Dis 2004; 47 (2): 105-15.
  7. Messerli F.H, Weber M.A, Brunner H.R. Angiotensin II receptor inhibition, a new therapeutic principle. Arch Intern Med 1996; 156 (17): 1957-65.
  8. Perry C.M. Azilsartan medoxomil: a review of its use in hypertension. Clin Drug Investig 2012; 32 (9): 621-39.
  9. Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336 (3): 801-8.
  10. Bönner G, Bakris G.L, Sica D et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin - converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27 (8): 479-86.
  11. Sica D, White W.B, Weber M.A et al. Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. J Clin Hypertens 2011; 13: 467-72.
  12. White W.B, Weber M.A, Sica D et al. Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension. Hypertension 2011; 57: 413-20.
  13. Metoki H, Ohkubo T, Kikuya M et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: The Ohasama study. Hypertension 2006; 47: 149-54.
  14. Kikuya M, Ohkubo T, Asayama K et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: The Ohasama study. Hypertension 2005; 45: 240-5.
  15. Hoshide S, Kario K, Hoshide Y et al. Associations between nondipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community - dwelling normotensives. Am J Hypertens 2003; 16: 434-8.
  16. Ohkubo T, Imai Y, Tsuji I et al. Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. Am J Hypertens 1997; 10: 1201-7.
  17. Kario K, Matsuno T, Kobayashi H et al. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27: 130-5.
  18. Kario K, Pickering T.G, Matsuo T et al. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001; 38: 852-7.
  19. Ohkubo T, Hozawa A, Yamaguchi J et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama study. J Hypertens 2002; 20: 2183-9.
  20. Rakugi H, Kario К, Enya К et al. Effect of azilsartan versus candesartan on nocturnal blood pressure variation in Japanese patients with essential hypertension. Blood Press 2013; 22 (S1): 22-8.
  21. Uzu T, Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1999; 100: 1635-8.
  22. Sherwood A, Steffen P.R, Blumenthal J.A et al. Night - time blood pressure dipping: The role of the sympathetic nervous system. Am J Hypertens 2002; 15: 111-8.
  23. Grassi G, Seravalle G, Quarti-Trevano F et al. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension 2008; 52: 925-31.
  24. Kario K, Schwartz J.E, Pickering T.G. Changes of nocturnal blood pressure dipping status in hypertensives by night - time dosing of - adrenergic blocker, doxazosin: Results from the HALT study. Hypertension 2000; 35: 787-94.
  25. Anan F, Takahashi N, Ooie T et al. Role of insulin resistance in nondipper essential hypertensive patients. Hypertens Res 2003; 26: 669-76.
  26. Della Mea P, Lupia M, Bandolin V et al. Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am J Hypertens 2005; 18: 30-5.
  27. Burnier M, Zanchi A. Blockade of the renin - angiotensin - aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24 (1): 11-25.
  28. Sodhi C.P, Kanwar Y.S, Sahai A. Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II - induced proliferation in VSM cells. Am J Physiol Heart Circ Physiol 2003; 284 (3): H846-H852.
  29. Arun K.H, Kaul C.L, Ramarao P. AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats. Cardiovasc Res 2005; 65 (2): 374-86.
  30. Sueta D, Kataoka К, Koibuchi N et al. Novel Mechanism for Disrupted Circadian Blood Pressure Rhythm in a Rat Model of Metabolic Syndrome - The Critical Role of Angiotensin II. Hypertension 2013; 2: e000035.

© ООО "Консилиум Медикум", 2014

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах